Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
KeyCorp's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $21.3B | |
|---|---|---|
| Revenue (ttm) | 7.6B | |
| Net income (ttm) | 2B | |
| EPS (ttm) | $1.82 | |
| Shares out | 1.1B | |
| P/E (trailing) | 11.6x | |
| P/E (forward) | 9.9x | |
| Dividend | $0.82 (3.86%) | |
| Volume | 15,679,438 | |
| Beta | 1.09 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $1.82B | $1.59B | $1.44B | $1.64B | $1.75B | -1.0% |
| Gross profit | $7.46B | $7.03B | $5.73B | $4.06B | $6.97B | -1.7% |
| Operating income | $3.25B | $3.22B | $1.16B | $-306.0M | $2.30B | -8.3% |
| Net income | $2.63B | $1.92B | $967.0M | $-161.0M | $1.83B | -8.6% |
| EPS (diluted) | $2.63 | $1.93 | $0.88 | $-0.32 | $1.52 | -12.8% |
| EBITDA | $3.29B | $3.36B | $1.31B | $-233.0M | $2.33B | -8.3% |
| R&D | — | — | — | — | — | — |
| SG&A | $2.69B | $2.66B | $2.66B | $2.78B | $3.20B | +4.4% |
Recent company headlines from major financial publishers.
The Base scenario reflects the modal expected operating path. Structural fixed-rate repricing across the asset pipeline steadily lifts net interest margin into the guided range by late FY2026. Controlled overhead expansion generates positive operating leverage, advancing diluted EPS toward consensus targets in FY2026 and FY2027. Capital generation funds the planned share repurchase program while maintaining robust regulatory capital ratios.
In the Bull scenario, KeyCorp accelerates fixed-rate asset reinvestment at premium yields while deposit costs fall faster than expected due to disciplined beta management. Commercial borrowing surges across KeyBanc Capital Markets verticals, lifting C&I loan growth and investment banking fees. Operating efficiency improves rapidly, driving ROTCE expansion and supporting enhanced capital return, propelling valuation toward $35.57.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 7.2% | $25.0 | $26.2 | $27.6 | $29.4 | $31.6 |
| 8.0% | $22.9 | $23.8 | $24.9 | $26.2 | $27.7 |
| 8.7% | $21.2 | $21.9 | $22.8 | $23.7 | $24.8 |
| 9.5% | $19.8 | $20.4 | $21.0 | $21.7 | $22.6 |
| 10.2% | $18.6 | $19.1 | $19.6 | $20.1 | $20.8 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
